|
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
06/26/2023
|
|
|
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
06/02/2023
|
|
|
Senseonics to Participate in the Jefferies Healthcare Conference
05/26/2023
|
|
|
Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results
05/09/2023
|
|
|
Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time
04/27/2023
|
|
|
Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
04/18/2023
|
|
|
Senseonics Announces Equity Grants To Employees Under Inducement Plan
04/05/2023
|
|
|
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
03/15/2023
|
|
|
Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023
02/17/2023
|
|
|
Senseonics Announces Equity Grants To Employees Under Inducement Plan
01/05/2023
|
|